Lorusso D, Ferrandina G, Colombo N, et al. - Researchers assessed progression free survival (PFS) in patients suffering from advanced (FIGO stage III-IV) or recurrent endometrial cancer (EC) and were treated with Carboplatin-Paclitaxel standard dose for 6–8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity, using randomization, in this phase II trial. They found that there was no significant increase in PFS in relation to treatment with bevacizumab combined with chemotherapy in patients with advanced/recurrent EC in the MITO END-2 trial. However, some effectiveness of the antiangiogenic agent was indicated by these preliminary data.